ClinicalTrials.gg
Active, not recruitingNCT06015503KANNONUpdated May 22, 2026

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)

A Phase 2 interventional study of PLB1004 in NSCLC (Non-small Cell Lung Cancer), sponsored by Avistone Biotechnology Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Avistone Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 10 under way, 2 of them phase 3. andamertinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
5th of 11
139 · median 120
Started
2023
with 2 others
Phase 2
4 of 11
3 open now
Registered
2nd of 11
by date
Lead sponsor
8 of 11
Avistone Biotechnology Co., Ltd.

Among the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by planned enrollment, is one of 3 that started in 2023, is one of 4 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

9 of the 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About andamertinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing andamertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

It is a phase Ⅱ,open-label, single-line, Multiple cohorts, Multicenter study assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins mutation patients with Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC).

Read the detailed description

This a three-stage study consist a Screening Phase (Day -28 to -1), a Treatment Phase (until treatment discontinuation), and a Follow-up Phase (including end of treatment visit (EOT),end of study visit(EOS), safety follow-up and survival follow-up).

03

Conditions studied

  • NSCLC (Non-small Cell Lung Cancer)

Keywords

  • Non-Small-Cell Lung Cancer
  • EGFR
  • NSCLC
  • Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Ability to understand and willingness to sign a written document.
  2. Aged at least 18 years old.
  3. or cytologically confirmed locally advanced or NSCLC (stage IIIB\~IV).
  4. According to the prior treatments having received for advanced disease (platinum containing or/and immunotherapy containing systemic therapy, not more than three lines), participants were divided into two cohorts。
  5. Participants with EGFR ex20ins mutation.
  6. performance status 0 to 1.
  7. is not less than 12 weeks.
  8. At least one as defined by RECISTV1.1.
  9. Participants must have specific organ and bone marrow function.

Exclusion Criteria:

  • Exclusion

    1. Having the anticancer therapy prior to the first dose of PLB1004 as follows:

      1. Any monoclonal antibodies targeting EGFR//VEGFR within 4 weeks.
      2. Any cytotoxic drugs or other anticancer drugs from a previous treatment regimen within 14 days.
      3. Any anticancer herbal medicine within 7 days
      4. Major surgery within 4 weeks prior to starting PLB1004 or who have not recovered from side effects of such procedure except for the of Thoracoscopy and the clinical test of Mediastinoscopy could ≤ 7 days prior to starting PLB1004..
      5. Radiotherapy to lung fields and whole-brain fields ≤4 weeks prior to starting PLB1004. For all other anatomic sites, radiotherapy ≤2 weeks prior to starting PLB1004 or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions is not included.
      6. Any anti-EGFR TKI for the EGFR ex20ins mutation.
      7. Any third-generation anti-EGFR TKI during the treatment having achieved a best overall response of the partial response or complete response.
    2. Had not recovered from the adverse events and comorbidities caused by prior Systemic chemotherapy ,surgery ,radiotherapy to ≤ Grade 1(except for hair loss and permanent radiotherapy damage ),the neurological toxicity caused by platinum could ≤ Grade 2.
    3. Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with PLB1004 and for the duration of the study:

      • Strong inhibitors of
      • Strong inducers of CYP3A4
      • metformin a MATE transporter substrate
    4. Patients with spinal cord compression ,brain membrane metastasis and symptomatic central nervous system (CNS), who are neurologically unstable or have required increasing doses of within the 2 weeks prior to study manage CNS symptoms.
    5. Patients with uncontrolled and symptomatic pleural effusions, peritoneal effusions and pericardial effusions within 4 weeks prior to the start of treatment with PLB1004.
    6. Presence or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent that currently do not require treatment, and completely resected carcinoma in situ of any type.
    7. Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
    8. Konwn positive (hepatitis B virus , HBV) surface antigen(HBsAg) and HBV-DNA test value≥.
    9. known positive antibody(anti-HCV) and Anti-(+).Note: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible.
    10. Having significant or uncontrolled systemic disease, including but not limited to:

      1. Poorly controlled hypertension (referring to systolic blood pressure>100 mmHg after treatment) .
      2. Ongoing or active infection.
      3. Keratitis or onset of ulcerative keratitis.
      4. Other significant disease, mental illness or laboratory abnormalities that could affect the compliance of the patient on the protocol or investigator's judgement.
    11. , uncontrolled heart disease, including but not limited to:

      1. Abnormal on screening (ECG), defined as the average value of triplicate QTcF>470ms.
      2. Have significant arrhythmias such as ventricular arrhythmia, supraventricular arrhythmia which could not be controlled by drugs, nodal arrhythmia and other cardiac arrhythmias which could not be controlled by drugs, Grade≥3 of Congestive heart failure by the (NYHA).
      3. Any factors that increase the risk of QTc interval prolongation, such as hypokalemia, genetic long QT syndrome, taking drugs that causing the QT interval prolongation.
    12. Medical history of deep vein thrombosis or pulmonary embolism within 6 months prior to enrolment or any of the following: Myocardial infarction, unstable angina, stroke, , coronary/peripheral artery bypass graft, or any acute coronary syndrome. Or bleeding tendencies or hypercoagulable coagulopathy within 6 months prior to first dose.
    13. Have active digestive system disease, or major gastrointestinal surgery which may significantly affect the taking or absorption of PLB1004(such as ulcerative lesions, uncontrollable nausea, vomiting, diarrhea, and malabsorption syndrome).
    14. History of to active or inactive of PLB1004 or drugs with a similar chemical structure of class to PLB1004.
    15. pregnant or nursing women.
    16. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (estimated)

Study arms

  • Experimental
    PLB1004

    PLB1004 given alone as monotherapy

    Drug: PLB1004

Interventions

  • PLB1004 is a capsule in the form of 80mg and 40mg.

06

What researchers measure

Primary outcomes

  1. objective Response Rate (ORR)

    To evaluate the Objective Response Rate(ORR)which is defined by IRC as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1.

    Time frame: 3 years

Secondary outcomes

  1. objective Response Rate (ORR)

    To evaluate the Overall Response Rate(ORR)which is defined by investigator as the proportion of subjects with confirmed best overall response of complete response or partial response per RECIST v 1.1.

    Time frame: 3 years

  2. Disease Control Rate ( DCR)

    DCR is defined as the percentage of participants achieving complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1

    Time frame: 3 years

  3. Duration of Response (DOR)

    DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first.

    Time frame: 3 years

  4. Progression-Free Survival (PFS)

    PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1.

    Time frame: 3 years

  5. Overall Survival (OS)

    OS is defined as the time from the date of the first dose until the date of death due to any cause.

    Time frame: 3 years

  6. Intracranial Overall Response Rate(ORR)

    To evaluate the intracranial Overall Response Rate(ORR)which is defined by investigator as the proportion of subjects with Intracranial disease confirmed best overall response of complete response or partial response per RECIST v 1.1.

    Time frame: 3 years

  7. Intracranial Disease Control Rate (DCR)

    Intracranial DCR is defined as the percentage of participants achieving Intracranial disease complete or partial response or stable disease of at least 11 weeks as defined per RECIST v 1.1.

    Time frame: 3 years

  8. Intracranial Disease Control Rate (DOR)

    Intracranial DOR is defined as the time from the date of first documented response (CR or PR) until the date of Intracranial disease documented progression or death, whichever comes first.

    Time frame: 3 years

  9. Intracranial Progression-Free Survival (PFS)

    Intracranial PFS is defined as the time from the date the first dose until the date of objective disease progression or death by cause, whichever comes first, based on investigator review according to RECISTv1.1.

    Time frame: 3 years

  10. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug assessed by CTCAE v5.0.

    Time frame: 2 years

  11. Incidence of abnormalities in Clinical Laboratory Assessments.

    Number of participants with abnormalities in Clinical Laboratory tests(including serum chemistry and hematology) will be reported.

    Time frame: 2 years

  12. Incidence of abnormalities in Vital Signs.

    Number of participants with abnormalities in vital signs(including temperature ,pulse/heart rate,and blood pressure) will be reported.

    Time frame: 2 years

  13. Area Under the Curve(AUC0-t)of PLB1004

    The AUC values are based on the plasma concentration-time profile (from time 0 to Time of the Last Quantifiable Concentration) of PLB1004. To characterize the pharmacokinetics of PLB1004.

    Time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose

  14. Area Under the Curve(AUC0-∞)of PLB1004

    The AUC values are based on the plasma concentration-time profile (from time 0 to infinity) of PLB1004. To characterize the pharmacokinetics of PLB1004.

    Time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose

  15. Maximum plasma concentration (Cmax) of PLB1004

    The Cmax values are based on the plasma concentration-time profile of PLB1004. To characterize the pharmacokinetics of PLB1004.

    Time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose

  16. Time to maximum plasma concentration (Tmax) of PLB1004

    The Tmax values are based on the plasma concentration-time profile of PLB 1004.To characterize the pharmacokinetics of PLB1004.

    Time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose

  17. Half-life time (t1/2) of PLB1004

    The t1/2 values are based on the terminal disposition Phase Half-life for PLB1004 and its Active Metabolites. To characterize the pharmacokinetics of PLB1004.

    Time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose

  18. Apparent clearance (CL/F) of PLB1004

    The CL/F values are based on the apparent clearance after extravascular administration for PLB1004. To characterize the pharmacokinetics of PLB1004.

    Time frame: Time Frame: Up to approximately 28 days; pre-dose and multiple time points post-dose

07

Study locations

1 site
08

References and documents

Publications

  • Yang JJ, Mu Y, Wang ZH, Duan JC, Zhang Y, Wu L, Zhong H, Zhao J, Yao Y, Wang P, Li XL, Yang RX, Min XH, Lv DQ, Xu HP, Fu ZM, Shen B, Sun LH, Wang CL, Zhou JY, Xu RL, Ma HW, Zhao YQ, Shi HP, Zhang PL, Xue WZ, Han D, Zheng Y, Wu YL. Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study. J Thorac Oncol. 2026 Mar;21(3):103518. doi: 10.1016/j.jtho.2025.11.008. Epub 2025 Nov 15. PubMed 41248848 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Mar 2025, 19 months.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 19 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2023
First posted
Aug 29, 2023
StartActual
Jul 21, 2023
Primary completionActual
Mar 6, 2025
CompletionEst.
Dec 30, 2026
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06015503
Lead sponsor
Avistone Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Jul 21, 2023
Primary completion
Mar 6, 2025
Completion
Dec 30, 2026 (estimated)
Last update
May 22, 2026

Study contacts

Yilong Wu, MD
principal investigator · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andamertinib

Start the discussion